ATA3219

DRUG2 trials

Sponsors

Atara Biotherapeutics

Conditions

Lupus NephritisRelapsed/Refractory B-cell Non-Hodgkin LymphomaSystemic Lupus Erythematosus

Phase 1

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

TerminatedNCT06256484

Atara BiotherapeuticsRelapsed/Refractory B-cell Non-Hodgkin Lymphoma

Start: 2024-09-06End: 2025-03-30Updated: 2026-03-11

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

WithdrawnNCT06429800

Atara BiotherapeuticsLupus Nephritis, Systemic Lupus Erythematosus

Start: 2025-04-16End: 2025-04-16Updated: 2025-04-24